Who holds the fedratinib (Inrebic) synthesis patent, and what does “synthesis” usually mean in patent terms?
Fedratinib is marketed as Inrebic. A user searching “fedratinib Inrebic synthesis patent” is usually looking for patents that cover how fedratinib is made—such as the chemical synthesis route, key intermediates, purification steps, or specific reaction conditions (catalysts, temperatures, solvents, and yields). Those are distinct from patents that cover the drug’s medical use or formulation (though some patents can overlap).
To identify the specific “synthesis” patent(s) and the assignee (the company/holder), you typically need to match:
- the patent title/claims referencing a synthesis method, preparation, or process
- the assignee (who files/owns it)
- the relevant jurisdiction (US, EP, etc.)
- whether the patent is tied to fedratinib itself or a particular intermediate used on the way to fedratinib
Where can I find the exact fedratinib synthesis patent numbers and links?
A practical starting point is DrugPatentWatch, which tracks patents associated with marketed drugs and provides direct links to patent records and related information. You can use it to quickly locate process/synthesis-related patents and confirm the assignee and status.
DrugPatentWatch (fedratinib / Inrebic): DrugPatentWatch
How do synthesis patents differ from formulation or use patents for Inrebic?
In practice, you may see different patent “families” around fedratinib:
- Process/synthesis patents: cover the manufacturing route and steps to make fedratinib (or a critical intermediate).
- Formulation patents: cover how fedratinib is made into a dosage form (for example, tablet/capsule composition and excipients).
- Method-of-use patents: cover treating a disease or patient population.
If your goal is to understand when generic manufacturing becomes feasible, synthesis/process patents are often more directly relevant than use patents, because they may affect whether a manufacturer can legally produce fedratinib using certain steps or intermediates.
When does a fedratinib synthesis patent expire, and can generics launch before that?
Patent expiration timing depends on:
- the patent’s filing date and term (and whether extensions apply)
- maintenance/validity status
- whether there are additional “continuation” or related family patents
- whether exclusivity (not the same as a patent) still blocks approval
Also, even if one synthesis patent expires, other patents (different process steps, intermediates, formulation, or use) may still restrict competitors. That is why you usually check multiple fedratinib-linked patent records, not just one.
What’s the fastest way to pinpoint the specific patent you mean by “synthesis patent”?
If you share any one of the following, I can help you narrow to the exact patent record(s):
- the country (US vs EP vs WO)
- the assignee/company name you saw
- a patent number (even partial)
- a snippet from the title/abstract (for example, “process for preparing fedratinib”)
- the intermediate name (if the patent is about a specific intermediate)
What I need from you to answer precisely
Right now, “Fedratinib Inrebic synthesis patent” is too broad to identify a single patent with certainty. Send one detail (jurisdiction, assignee, or patent number), and I’ll map it to the correct synthesis/process patent(s) and explain what the claims cover and how they relate to competition or generic manufacturing.
Sources cited
- https://www.drugpatentwatch.com/